DrugPatentWatch Database Preview
Details for Patent: 8,858,996
Which drugs does patent 8,858,996 protect, and when does it expire?
This patent has thirty-five patent family members in twenty-two countries.
Summary for Patent: 8,858,996
Title: | Pharmaceutical compositions for the coordinated delivery of NSAIDS |
Abstract: | The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages. |
Inventor(s): | Plachetka; John R. (Chapel Hill, NC) |
Assignee: | Pozen Inc. (Chapel Hill, NC) |
Application Number: | 14/244,471 |
Patent Claim Types: see list of patent claims | Composition; Dosage form; Use; |
Drugs Protected by US Patent 8,858,996
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Horizon Pharma Usa | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-002 | Apr 30, 2010 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER | ➤ Sign Up | ||
Horizon Pharma Usa | VIMOVO | esomeprazole magnesium; naproxen | TABLET, DELAYED RELEASE;ORAL | 022511-001 | Apr 30, 2010 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER | ➤ Sign Up | ||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 8,858,996
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
8,557,285 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | ➤ Sign Up |
8,852,636 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | ➤ Sign Up |
8,865,190 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | ➤ Sign Up |
6,926,907 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 8,858,996
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 474559 | ➤ Sign Up | |||
Australia | 2002305758 | ➤ Sign Up | |||
Australia | 2006235929 | ➤ Sign Up | |||
Australia | 2009200966 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |